Achieve Life Sciences Files 2024 Annual Report
Ticker: ACHV · Form: 10-K · Filed: Mar 11, 2025 · CIK: 949858
| Field | Detail |
|---|---|
| Company | Achieve Life Sciences, Inc. (ACHV) |
| Form Type | 10-K |
| Filed Date | Mar 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, life-sciences, financing
TL;DR
ACHV 2024 10-K filed. Financials and operations detailed. Check for updates.
AI Summary
Achieve Life Sciences, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as OncoGenex Pharmaceuticals, Inc. and Sonus Pharmaceuticals Inc., is involved in the development of in vitro and in vivo diagnostic substances. The filing details financial information and business operations for the period, with specific references to events like warrants issued in August 2020 and a registered direct offering in February 2024.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of Achieve Life Sciences' financial health and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a life sciences company, Achieve Life Sciences is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year End (The report covers the fiscal year ending December 31, 2024.)
- 2025-03-11 — Filing Date (The 10-K was filed on March 11, 2025.)
Key Players & Entities
- Achieve Life Sciences, Inc. (company) — Filer of the 10-K
- OncoGenex Pharmaceuticals, Inc. (company) — Former name of Achieve Life Sciences
- Sonus Pharmaceuticals Inc (company) — Former name of Achieve Life Sciences
- 2024-12-31 (date) — Fiscal year end
- 2025-03-11 (date) — Filing date
- August 2020 (date) — Warrants issued
- February 2024 (date) — Registered direct offering
FAQ
What were the key financial highlights for Achieve Life Sciences in the fiscal year 2024?
The 10-K filing for the fiscal year ending December 31, 2024, provides detailed financial statements and disclosures, but specific dollar amounts for revenue, net income, or loss are not provided in the header information.
What significant corporate actions or events occurred in 2024 according to this filing?
The filing references a 'February 2024 Registered Direct Offering' as a significant event during the 2024 fiscal year.
What is the company's primary business focus?
Achieve Life Sciences, Inc. is involved in 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' as indicated by its Standard Industrial Classification code.
When did Achieve Life Sciences change its name?
The company was formerly known as OncoGenex Pharmaceuticals, Inc. (name change effective August 21, 2008) and prior to that, Sonus Pharmaceuticals Inc.
What is the company's principal executive office location?
The business and mail address for Achieve Life Sciences, Inc. is located at 22722 29th Dr. SE, Suite 100, Seattle, WA 98021.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 11, 2025 regarding ACHIEVE LIFE SCIENCES, INC. (ACHV).